Evidence map›Paper›PMID 33899052›Full record

ArticleNeurology (E-Cronicon)2021

Gut Microbiome Changes with Osteopathic Treatment of Constipation in Parkinson's Disease: A Pilot Study.

Jayme D Mancini, Sheldon Yao, Luis R Martinez, Haque Shakil, To Shan Li

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Neurology (E-Cronicon), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07176078 (Evaluating the Added Benefit of Osteopathic Care to a Flexi-FODMAP Diet in Fibromyalgia Patients With Irritable Bowel Syndrome), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07176078 narecruitingnot on this mapstarted 2026, after this paper: background citation

Evaluating the Added Benefit of Osteopathic Care to a Flexi-FODMAP Diet in Fibromyalgia Patients With Irritable Bowel Syndrome: a Randomized Sham-controlled Trial

TypeinterventionalSponsorUniversitair Ziekenhuis BrusselRan2026 to 2027Enrolled96ConditionsIrritable Bowel Syndrome (IBS), Fibromyalgia (FM)ArmsOsteopathic care, Sham Osteopathic care, Flexi-FODMAP Diet
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Heliyon · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jayme D ManciniNew York Institute of Technology College of Osteopathic Medicine, Northern Boulevard, Old Westbury, NY, USA.
Sheldon YaoNew York Institute of Technology College of Osteopathic Medicine, Northern Boulevard, Old Westbury, NY, USA.
Luis R MartinezDepartment of Oral Biology, University of Florida College of Dentistry, Gainesville, FL, USA.
Haque ShakilNew York Institute of Technology College of Osteopathic Medicine, Northern Boulevard, Old Westbury, NY, USA.
To Shan LiNew York Institute of Technology College of Osteopathic Medicine, Northern Boulevard, Old Westbury, NY, USA.
University of Florida · US

Funding

Unraveling Cryptococcus neoformans mechanisms of brain invasion and colonizationR01AI145559 · NIAID · UNIVERSITY OF TEXAS EL PASO · PI MARTINEZ, LUIS R · 2019 to 2023
$2.6M
NIAID NIH HHS R01 AI145559
6 · The paper itself

Abstract

introductionThe gut microbiome appears to be predictive of Parkinson's disease (PD) with constipation. Chronic constipation frequently manifests prior to motor symptoms and impairs quality of life. An osteopathic manipulative medicine (OMM) sequence used physical exam assessment and manual treatment of neuromusculoskeletal dysfunctions pertinent to constipation in PD for this prospective ABA-design study, IRB-NYITBHS1065. The effects of 4 weekly treatments on the gut microbiome among men and women over 40 years old with chronic constipation and PD were investigated. Severity of PD was rated with the Movement Disorders Society-Unified PD rating scale (UPDRS) in six subjects with constipation. Also, the Bristol stool scale and questionnaires validated for constipation were administered for diagnosis, symptom severity, and quality of life during a 4-week control-period (A), 4-weekly OMM-treatments (B), and 2-weeks no-intervention (A). Biweekly stool samples were assessed for normalized microbiota abundance.

resultsThe mean Bristol rating improved from type 2 (± 1) Pre-OMM to 3 (± 1; p = .167; d = 0.677) Post-OMM. Mean constipation severity significantly decreased (p = .010; d = 1.508) Post-OMM. Mean quality of life significantly improved (p = .041; d = 1.072) Post-OMM. The Pre-OMM mean number of families within the phylum Firmicutes decreased by 3 (p = .043; d = 1.177) Post-OMM. There were significant changes in the normalized abundance of phyla Actinobacteria (p = .040; d = 0.845) and Verrucomicrobia (p = .024; d = 0.675) as well as in genus Roseburia (p = .033; d = 1.109), Intestinimonas (p = .035; d = 0.627) and Anaerotruncus (p = .004) Post-OMM.

conclusionThe gut microbiome shifted among individuals with constipation and PD after four weekly treatments with the OMM-sequence. Changes in the gut microbiome Post-OMM were associated with UPDRS results and constipation measures. Clinical trials and studies to develop the gut microbiome into a validated biomarker for PD are necessary to understand the impact of OMM in patients with PD and constipation.

Indexed as

Autonomic Nervous SystemConstipationGastrointestinal SystemManual TherapyMicrobiotaParkinson’s Disease

Identifiers

PMID33899052
PMCPMC8061899
OpenAlexW3126930478

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.